These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1951080)

  • 41. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy.
    Biddle TL; Benotti JR; Creager MA; Faxon DP; Firth BG; Fitzpatrick PG; Konstam MA; Krebs C; Walton L; Kershner RP
    Am J Cardiol; 1987 Jun; 59(15):1345-50. PubMed ID: 3591689
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
    Lake-Bakaar GA; Singh MK; Kass PH; Griffiths LG
    J Vet Cardiol; 2015 Jun; 17(2):120-8. PubMed ID: 26007710
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Chronic therapy of congestive cardiomyopathy: effects of prenalterol and digoxin].
    Schwarz KR; Hofmann M; Mäurer W; Kadel C; von Olshausen K; Rauch B; Kübler W
    Z Kardiol; 1985 Jul; 74(7):374-83. PubMed ID: 3929486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of milrinone on complex ventricular arrhythmias in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Ludmer PL; Baim DS; Antman EM; Gauthier DF; Rocco MB; Friedman PL; Colucci WS
    Am J Cardiol; 1987 Jun; 59(15):1351-5. PubMed ID: 3591690
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety of ibopamine therapy in congestive heart failure. Ibopamine cohort study: baseline and 1-year results.
    Sher D; Licciardello L; Ferrari V; Sirtori F; Cesana B
    Arzneimittelforschung; 1991 Apr; 41(4):402-9. PubMed ID: 1859514
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.
    Osterziel KJ; Strohm O; Schuler J; Friedrich M; Hänlein D; Willenbrock R; Anker SD; Poole-Wilson PA; Ranke MB; Dietz R
    Lancet; 1998 Apr; 351(9111):1233-7. PubMed ID: 9643742
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy.
    O'Grady MR; Minors SL; O'Sullivan ML; Horne R
    J Vet Intern Med; 2008; 22(4):897-904. PubMed ID: 18537880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: one-year follow-up results of the randomized trial.
    Wojnicz R; Nowak J; Szyguła-Jurkiewicz B; Wilczek K; Lekston A; Trzeciak P; Nowalany-Kozielska E; Zembala M; Wodniecki J; Poloński L
    Am Heart J; 2006 Oct; 152(4):713.e1-7. PubMed ID: 16996844
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oscillatory hyperventilation in severe congestive heart failure secondary to idiopathic dilated cardiomyopathy or to ischemic cardiomyopathy.
    Kremser CB; O'Toole MF; Leff AR
    Am J Cardiol; 1987 Apr; 59(8):900-5. PubMed ID: 3825954
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of OPC-8212, a new positive inotropic agent, on canine ventricular arrhythmias.
    Hashimoto K; Mitsuhashi H
    Br J Pharmacol; 1986 Aug; 88(4):915-21. PubMed ID: 3742163
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chronic oral amrinone therapy in congestive heart failure: a double-blind placebo-controlled withdrawal study.
    Evans JR; Pacht K; Huss P; Unverferth DV; Bashore TM; Leier CV
    Int J Clin Pharmacol Res; 1984; 4(1):9-18. PubMed ID: 6381344
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
    Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN
    Am J Cardiol; 1996 May; 77(12):1078-82. PubMed ID: 8644661
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of imazodan for treatment of chronic congestive heart failure. The Imazodan Research Group.
    Goldberg AD; Nicklas J; Goldstein S
    Am J Cardiol; 1991 Sep; 68(6):631-6. PubMed ID: 1715125
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single-centred experience with levosimendan in paediatric decompensated dilated cardiomyopathy.
    Séguéla PE; Mauriat P; Mouton JB; Tafer N; Assy J; Poncelet G; Nubret K; Iriart X; Thambo JB
    Arch Cardiovasc Dis; 2015; 108(6-7):347-55. PubMed ID: 25863426
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The effect of captopril on the immediate quality of life in patients with congestive heart failure].
    Han Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 1992 Jun; 20(3):154-6. PubMed ID: 1289024
    [No Abstract]   [Full Text] [Related]  

  • 56. Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? II. Protagonist's viewpoint.
    Packer M
    J Am Coll Cardiol; 1988 Aug; 12(2):562-6. PubMed ID: 3392349
    [No Abstract]   [Full Text] [Related]  

  • 57. Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Hagemeijer F; Brand HJ; van Mechelen R
    Am J Cardiol; 1989 Mar; 63(9):571-6. PubMed ID: 2919561
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.
    Colucci WS; Elkayam U; Horton DP; Abraham WT; Bourge RC; Johnson AD; Wagoner LE; Givertz MM; Liang CS; Neibaur M; Haught WH; LeJemtel TH
    N Engl J Med; 2000 Jul; 343(4):246-53. PubMed ID: 10911006
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: results of the vesnarinone trial withdrawal substudy. Vest Withdrawal Substudy Group.
    Soran O; Young JD; Holubkov R; Loftus S; Bourge R; Carson P; Jaski B; White BG; Feldman AM
    J Card Fail; 1999 Sep; 5(3):195-200; discussion 201-2. PubMed ID: 10496192
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mode and mechanism of action of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, on the dog heart.
    Taira N; Endoh M; Iijima T; Satoh K; Yanagisawa T; Yamashita S; Maruyama M; Kawada M; Morita T; Wada Y
    Arzneimittelforschung; 1984; 34(3A):347-55. PubMed ID: 6331465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.